Background: In recent times, the “epidemic of obesity” arose as one of the major global health apprehensions. Since lifestyle amendments alone are often perplexing and inadequate for the maintenance of weight reduction, pharmacotherapy should be considered in an appropriate manner for obesity patients with weight-related comorbidities. Recent advances in anti-obesity medicines have enabled the eventuality of achieving clinically significant weight loss. Still, they've a high cost and may beget adverse issues depending on the existent patient. Our study also sheds light on various long term studies done in comparision of tirzepatide with other anti-obese drugs. Our review provides an overview on the currently available and FDA approved anti-obesity medications along with the only anti-obesity drug Tirzepatide, approved recently by Central Drug Standard Control in India in June 2024. Based on many studies Tirzepatide was better compared to other drugs in terms of weight reduction and maintenance of lost weight.